<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04009720</url>
  </required_header>
  <id_info>
    <org_study_id>S2361</org_study_id>
    <nct_id>NCT04009720</nct_id>
  </id_info>
  <brief_title>RESPOND EDGE Post Market Study</brief_title>
  <acronym>RESPOND EDGE</acronym>
  <official_title>Repositionable Lotus Edge™ Valve System - Post Market Evaluation of Real World Clinical Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the RESPOND EDGE post market study is to collect real world clinical and&#xD;
      device performance outcomes data with the Lotus Edge™ Valve System used in routine clinical&#xD;
      practice to demonstrate that the commercially available Lotus Edge Valve System is a safe and&#xD;
      effective treatment for patients with severe calcific aortic stenosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The RESPOND EDGE study is a prospective, open label, single arm, multi-center, observational&#xD;
      post market study designed to collect real world clinical and device performance outcomes&#xD;
      data of the commercially available Lotus Edge Valve used in routine clinical practice for the&#xD;
      treatment of severe calcific aortic stenosis. Approximately 200 real-world, consecutive&#xD;
      subjects will be enrolled at up to 20 study centers. The study duration for each subject is&#xD;
      expected to be approximately 2 years. Implanted subjects will be contacted for follow-up at&#xD;
      30 days, 1 and 2 years post index procedure. Subjects who are enrolled but not implanted with&#xD;
      a Lotus Edge valve will be followed for safety through 30 days after the initial attempted&#xD;
      index procedure.&#xD;
&#xD;
      Collection of safety events will include any serious adverse event (SAE), serious adverse&#xD;
      device effect (SADE), adverse device effect (ADE), unanticipated serious adverse device&#xD;
      effect (USADE), and all Valve Academic Research Consortium (VARC) events regardless of&#xD;
      seriousness and device relationship through 2 year follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    study device Lotus Edge was removed from the market&#xD;
  </why_stopped>
  <start_date type="Actual">October 11, 2019</start_date>
  <completion_date type="Actual">June 2, 2021</completion_date>
  <primary_completion_date type="Actual">December 9, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>All-cause mortality (Primary Safety Endpoint)</measure>
    <time_frame>30 days</time_frame>
    <description>The primary safety endpoint is all-cause mortality at 30 days after the implant procedure. The primary safety endpoint will be evaluated on an intention to- treat (ITT) basis (all subjects enrolled, whether or not a Lotus Edge Valve is implanted).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean aortic valve pressure gradient (Primary Effectiveness Endpoint)</measure>
    <time_frame>Within 7 days after the index procedure (Pre-discharge)</time_frame>
    <description>The primary effectiveness endpoint is the mean aortic valve pressure gradient (mmHg) at pre-discharge as determined by an independent core laboratory. The primary analysis set for the primary effectiveness endpoint is the implanted analysis set.</description>
  </primary_outcome>
  <enrollment type="Actual">200</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lotus Edge Device</intervention_name>
    <description>The LOTUS Edge Valve System is indicated to improve aortic valve function for symptomatic subjects with severe calcific aortic stenosis (aortic valve area [AVA] &lt;1.0 cm2 or AVA index &lt;0.6 cm2/m2) who are at high risk for standard surgical valve replacement.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All subjects who are candidates for Transcatheter Aortic Valve Implantation (TAVI), signed&#xD;
        the Informed Consent Form and are selected to receive a LOTUS Edge valve will be evaluated&#xD;
        for enrollment in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Subjects will be evaluated for eligibility by the clinical center's heart team per the&#xD;
        local standard of practice in accordance with the Directions for Use.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Dumonteil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Pasteur</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rajesh K Kharbanda, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oxford Heart Centre, John Radcliffe Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Helsinki</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Universität Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galway University Hospital</name>
      <address>
        <city>Galway</city>
        <zip>H91 YR71</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az Osp Univ Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC - Thorax Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Lund</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Belfast</name>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The General Infirmary</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 2, 2019</study_first_submitted>
  <study_first_submitted_qc>July 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>July 11, 2021</last_update_submitted>
  <last_update_submitted_qc>July 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

